Objectives: To collect recent data on the susceptibility of anaerobes and to compare them with results from previous studies.
Introduction
Anaerobic bacteria are commonly found in polymicrobial infections. Antimicrobial therapy for the management of infections with a high probability of anaerobic aetiology includes an antimicrobial agent with known efficacy against anaerobes.
Antibiotic resistance among anaerobic bacteria has increased in recent years and it has been reported against antibiotics that were previously thought to be universally active, such as carbapenems and imidazoles. 1 Since anaerobic cultures are cumbersome and susceptibility testing of anaerobic isolates is generally not performed routinely, it is important to have good knowledge of background susceptibility to avoid the use of inappropriate empirical antibiotics. Therefore, it is recommended to periodically monitor local and regional resistance patterns.
2 Two multicentre surveys have already been performed in Belgium, the first one in 1987 3 and the second one in 1993-94. 4 Since that time no published data are available about antimicrobial susceptibility of anaerobic bacteria. The objective of this study was to collect recent data on the susceptibility of anaerobes in our country. The results were analysed in reference to the previous surveys.
Materials and methods

Bacteria
Strains were collected from October 2003 to February 2005 in 8 Belgian university hospitals and one general hospital: Academisch Ziekenhuis Vrije Universiteit Brussel (Brussels), Hôpital Universitaire Erasme (Brussels), Cliniques Universitaires Saint-Luc (Brussels), Universitair Ziekenhuis Antwerpen (Antwerp), Universitair Ziekenhuis Leuven (Leuven), Centre Hospitalier Universitaire du Sart-Tilman (Liège), Cliniques Universitaires de Mont-Godinne (Yvoir), Algemeen Ziekenhuis Sint-Jan (Brugge) and Universitair Ziekenhuis Gent (Ghent). Six of these centres participated in the previous surveys. Each centre collected prospectively up to 50 unselected, nonduplicated clinically significant strict anaerobic isolates. Specimen source was recorded for each isolate. The isolates were sent for susceptibility testing to the microbiology laboratory of the Academisch Ziekenhuis Vrije Universiteit Brussel.
Identification
Species identification was performed by standard methods in the collecting laboratories. Identification was checked at the Academisch Ziekenhuis Vrije Universiteit Brussel by analysis of cellular fatty acid composition using the Microbial Identification System (MIS), followed by appropriate biochemical or enzymatic tests 5 if the MIS results did not support the identification of the collecting laboratory.
Susceptibility testing
The antibiotic susceptibility was determined by Etest Ò methodology (AB Biodisk, Solna, Sweden), which was previously shown to produce accurate results for susceptibility testing of anaerobic bacteria. 6 Brucella agar supplemented with laked sheep blood, haemin and vitamin K1 was used as recommended for the CLSI (formerly NCCLS) reference agar dilution procedure. 2 The following antimicrobial agents were tested: penicillin, amoxicillin/clavulanic acid, clindamycin, metronidazole, meropenem, chloramphenicol, cefoxitin, cefotetan, moxifloxacin, linezolid and piperacillin/tazobactam. The agar plates were inoculated with a McFarland 1 suspension and incubated in anaerobiosis. The results were read after 48 h. For slow growers, reading was performed after 72 h. Interpretation was carried out according to the manufacturer's recommendations. Because of the unavailability of tigecycline Etest Ò strips when the study was performed the MIC of this antimicrobial agent was determined by the CLSI agar dilution procedure.
2 Bacteroides fragilis ATTC 25285, Bacteroides thetaiotaomicron ATCC 29741 and Eubacterium lentum ATCC 43055 were included as control strains in each test run. The isolates were categorized by using the following breakpoints for susceptible and resistant strains, respectively: penicillin 2 0. 
Results
Four hundred and forty-three (443) anaerobic isolates were collected from various sources: 151 from abdominal sites, 98 from blood, 70 from wounds and pus, 46 from abscesses, 14 from the respiratory tract, 11 from gynaecological and obstetrical sites, 6 from the central nervous system, 6 from ear and sinus, and 41 from miscellaneous other sites. Table 1 summarizes the susceptibility results for the different groups of anaerobes. Table 2 compares the percentages of susceptible strains in this present survey with those found in the 1993-94 and 1987 surveys. The distribution of individual species is presented in the footnotes of Table 1 for the strains of this study and can be found in original reports for the previous surveys. 3, 4 Overall, b-lactamases were detected in 62% of the 443 isolates. Most b-lactamase-producing strains belong to the B. fragilis group (98% b-lactamase-positive) and to the group of Prevotella spp. and other Gram-negative bacilli (70% b-lactamase-positive). As compared with the previous surveys of 1987 and 1993-94, the percentage of b-lactamase-producing strains increased in this last group from 31% to 57% and 70%, respectively. Among Clostridium spp. 5 b-lactamase-producing clostridia (3 Clostridium clostridioforme, 1 Clostridium tertium and 1 Clostridium spp.) out of 57 isolates (9%) were detected in this study. In 1993-94 only one b-lactamase-positive Clostridium isolate was found. In 1987 all clostridia were b-lactamase-negative. All other organisms including all Fusobacterium were b-lactamasenegative in the three surveys.
Penicillin, a compound very susceptible to b-lactamases, was active against only 1% of B. fragilis group strains, a result similar to that of the previous studies. The susceptibility of Prevotella spp. and other Gram-negative bacilli decreased markedly from 64% in 1987 to 48% in 1993-94 and to only 26% in this survey. Penicillin activity was much better against other anaerobic isolates. However, a decrease in the prevalence of penicillinsusceptible isolates was seen in Clostridium spp., non-sporeforming Gram-positive bacilli and anaerobic cocci from 91%, 93% and 92% in 1987 to 83%, 81% and 84% in this survey, respectively. In contrast, all Fusobacterium isolates in this survey were susceptible to penicillin compared with 70% and 88% in 1987 and 1993-94, respectively.
The activity of cefoxitin was less affected by the b-lactamases: 62% of B. fragilis group strains and 98% of Prevotella spp. and other Gram-negative bacilli were susceptible. Eighty-six percent (86%) of B. fragilis strains were susceptible as opposed to 30% of strains belonging to other species of the B. fragilis group. The susceptibility rates of all other groups of anaerobes were high (>90%).
Cefotetan was less active than cefoxitin against anaerobic Gram-negative bacilli: 52% of B. fragilis group strains and 86% Two b-lactam/b-lactamase inhibitor combinations were tested in this study: amoxicillin/clavulanic acid and piperacillin/ tazobactam. The activity of the b-lactam antibiotic was partially restored by the addition of a b-lactamase inhibitor. Overall activities of amoxicillin/clavulanic acid and piperacillin/ tazobactam in this survey were 92% and 96%, respectively. In the previous surveys susceptibility to these combinations was >95% (piperacillin/tazobactam was not tested in 1987). Resistance to amoxicillin/clavulanic acid is limited to the B. fragilis group, with the exception of a few intermediate Clostridium spp. strains. In the B. fragilis group, 92% of B. fragilis and 78% of other B. fragilis group strains were susceptible to amoxicillin/clavulanic acid in this survey, as compared with 95% and 89% in 1993-94 and 97% and 94% in 1987, respectively. Four hundred and twentysix (426) isolates were susceptible to piperacillin/tazobactam, 10 intermediate (5 B. thetaiotaomicron, 2 Bacteroides vulgatus and 3 Veillonella parvula) and 7 resistant (1 B. stercoris, 2 B. thetaiotaomicron, 1 Bacteroides uniformis, 1 Bilophila wadsworthia and 2 C. clostridioforme).
Chloramphenicol was very active against all anaerobic isolates (98% overall) with susceptibility exceeding 95% in all groups. Susceptibility to metronidazole remains stable. Overall susceptibility was 95% and was high in all groups except non-sporeforming Gram-positive bacilli: all Propionibacterium acnes (19 isolates) and one Lactobacillus sp. were resistant. Overall activity of clindamycin decreased from 83% in 1987 to 72% in 1993-94 and to 63% in this survey. Only 33% of non-B. fragilis strains in the B. fragilis group were susceptible to clindamycin, as compared with 60% of B. fragilis strains. For moxifloxacin, MIC 50 and MIC 90 were 1 and >32 mg/L. Overall susceptibility to 1 mg/L moxifloxacin was 64%. In the Includes Bacteroides capillosus (1 strain), Bacteroides ureolyticus (1 strain), Bilophila wadsworthia (2 strain), Capnocytophaga ochracea (1 strain), Capnocytophaga sputigena (1 strain), Porphyromonas endodontalis (1 strain), Prevotella bivia (8 strains), Prevotella buccae (5 strains), Prevotella denticola (1 strain), Prevotella intermedia/nigrescens (3 strains), P. intermedia/nigrescens (2 strains), Prevotella melaninogenica (4 strains), P. melaninogenica group (2 strains), Prevotella oralis (5 strains), Prevotella oris (3 strains), Prevotella species (9 strains), Prevotella tannerae (1 strain). d Includes Clostridium bifermentans (1 strain), Clostridium clostridioforme (3 strains), Clostridium glycolicum (2 strains), Clostridium innocuum (1 strain), Clostridium perfringens (37 strains), Clostridium ramosum (3 strains), Clostridium septicum (2 strains), Clostridium sordelli (1 strain), Clostridium species (2 strains), Clostridium sporogenes (1 strain), Clostridium subterminale (1 strain) and Clostridium tertium (3 strains). B. fragilis group, 68% of B. fragilis and 30% of non-B. fragilis strains were susceptible to moxifloxacin at this breakpoint. In other groups susceptibility was 80% for Fusobacterium spp., 70% for Prevotella spp. and other Gram-negative bacilli, 86% for Clostridium spp., 90% for non-spore-forming Gram-positive bacilli and 68% for anaerobic cocci. MIC 50 and MIC 90 of tigecycline were 0.5 and 8 mg/L, respectively. At the susceptibility breakpoint of 2 mg/L, 84% of isolates were susceptible to tigecycline; 73% in the B. fragilis group and 84% in Clostridium spp. All other isolates were susceptible at this breakpoint.
Discussion
Mixed polymicrobial infections involving anaerobic bacteria are most commonly treated empirically, without any laboratory documentation by cultures and susceptibility testing. Over the past 20 years, however, significant antibiotic resistance has been identified among several species of anaerobic bacteria. Many Gram-negative anaerobes presently display unpredictable susceptibilities to antimicrobial agents, which may result in an inappropriate choice of empirical antimicrobial therapy. Until recently, there was no consensus about the influence of antimicrobial resistance on the clinical outcome of infections involving anaerobes. 9, 10 The often polymicrobial nature of the infection and the contribution of surgical drainage may indeed obscure the importance of resistant organisms. Two studies underscore the importance of appropriate choice of therapy. A Finnish retrospective study 9 including 57 patients with clinically significant anaerobic bacteraemia evaluated the effect of the choice of antimicrobial therapy on the outcome for patients. Twenty-eight patients received appropriate antimicrobial treatment; for 18 patients (32%) an initially inappropriate therapy was changed on the basis of the bacteriological results and for 11 patients the treatment remained unchanged and was not adjusted to the laboratory results. In these three groups, the mortality rate was 18%, 17% and 55%, respectively. Overall, b-lactamase-producing strains increased from 41% in 1987 and 48% in 1993-94 to 62% in this survey. This rise can be partly attributed to a change in the species distribution. In 1987 and 1993-94, 56% and 58% of Gram-negative bacilli, respectively, were included in contrast to 71% in this survey. As expected, a high rate of b-lactamase-producing strains was recorded in the B. fragilis group (98%), corroborating the CLSI recommendation to report all members of the B. fragilis group as resistant to penicillin.
2 Remarkable was the continuous increase in b-lactamase positivity, up to 70% of the Prevotella spp. and other Gram-negative bacilli group, and the appearance of b-lactamasepositive Clostridium spp. strains (9%).
Overall 66% of strains were found to be not susceptible to penicillin. This antibiotic is no longer useful in empirical treatment of anaerobic infections. Previously it was considered the drug of choice for anaerobic infections above the diaphragm. However, taking into account the increasing resistance to penicillin of Prevotella spp., often present in oropharyngeal Belgium and Bristol-Myers Squibb Belgium. S. L. received support for attendance to an international conference from Wyeth Pharmaceuticals Belgium and was a member of the Advisory Board for the Belgian/Luxembourg Version of the Sanford Guide to Antimicrobial Therapy (GlaxoSmithKline Belgium). I. V., M. R., K. V., G. C. and Y. G. have none to declare.
